Progyny, Inc.
No SEC Form 4 filings for $PGNY in the last 30 days.
Progyny, Inc. (Nasdaq: PGNY) said its board approved a share repurchase program to buy back up to $200 million of common stock, funded from available cash. Repurchases may be made via open-market transactions, including Rule 10b5-1 plans, and can be suspended or ended anytime, according to the company.
Canaccord Genuity has upgraded Progyny (PGNY) to "Buy" from "Hold" and increased its price target to $30 from $19. This adjustment reflects a positive outlook on the managed healthcare company. Progyny specializes in fertility and family building benefits solutions, serving approximately 6.7 million employees and partners through its Smart Cycle approach and Progyny Rx.
Progyny Inc. (US74340E1038) is positioned as a key player in the growing U.S. fertility benefits market, providing an employer-sponsored platform that covers a range of fertility and family-building services. The company's model emphasizes high-touch support, data analytics for optimized outcomes, and partnerships with top clinics, creating predictable cash flows tied to employment trends. With strong retention rates and a focus on specialized services, analysts maintain a positive outlook for Progyny despite potential risks from regulatory changes or intensified competition.
